Trial Profile
A prospective trial of anti-TNF [tumour necrosis factor]-alpha chimeric monoclonal antibody (infliximab, Remicade) on insulin sensitivity, beta cell function and cardiovascular risk profile in insulin resistant human obesity
Status:
Completed
Phase of Trial:
Phase IV
Latest Information Update: 10 Nov 2021
Price :
$35
*
At a glance
- Drugs Infliximab (Primary)
- Indications Insulin resistance; Metabolic syndrome; Obesity
- Focus Pharmacodynamics
- 04 Apr 2008 New trial record.